We are live on ! Find out more
PRAH

PRA Health Sciences, Inc.
PRAH

Delisted

PRAH was delisted on the 30th of June, 2021.

261 hedge funds and large institutions have $4.78B invested in PRA Health Sciences, Inc. in 2017 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 121 increasing their positions, 70 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 15

73% more repeat investments, than reductions

Existing positions increased: 121 | Existing positions reduced: 70

21% more call options, than puts

Call options by funds: $7.62M | Put options by funds: $6.29M

11% more funds holding

Funds holding: 236261 (+25)

3% more capital invested

Capital invested by funds: $4.66B → $4.78B (+$117M)

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

Holders
261
Holders Change
+25
Holders Change %
+10.59%
% of All Funds
6.51%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.15%
New
45
Increased
121
Reduced
70
Closed
15
Calls
$7.62M
Puts
$6.29M
Net Calls
+$1.33M
Net Calls Change
+$10.8M
Name Holding Trade Value Shares
Change
Change in
Stake
LCG
126
Lisanti Capital Growth
New York
$2.41M +$452K +5,975 +23%
EI
127
EAM Investors
California
$2.41M -$720K -9,528 -23%
RIM
128
Rainier Investment Management
Washington
$2.35M -$910K -12,040 -28%
CEP
129
Chicago Equity Partners
Illinois
$2.3M +$133K +1,760 +6%
ERSOT
130
Employees Retirement System of Texas
Texas
$2.29M
CIC
131
Carnegie Investment Counsel
Ohio
$2.21M +$621K +8,211 +43%
DekaBank Deutsche Girozentrale
132
DekaBank Deutsche Girozentrale
Germany
$2.16M
UBS AM
133
UBS AM
Illinois
$2.11M +$429K +5,679 +26%
FDCDDQ
134
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.06M
3C
135
361 Capital
Colorado
$2.05M +$2.03M +26,893 New
HI
136
HBK Investments
Texas
$2M +$1.45M +19,130 +269%
AG
137
Algert Global
California
$1.94M -$335K -4,432 -15%
CAM
138
Congress Asset Management
Massachusetts
$1.92M +$1.9M +25,187 New
SEC
139
Seven Eight Capital
New York
$1.9M +$1.04M +13,700 +122%
AAMU
140
AEGON Asset Management (UK)
United Kingdom
$1.84M +$631K +8,352 +53%
CIC
141
Chase Investment Counsel
Virginia
$1.82M -$368K -4,870 -17%
SCM
142
Stevens Capital Management
Pennsylvania
$1.79M +$1.78M +23,506 New
GCP
143
GSA Capital Partners
United Kingdom
$1.75M -$1.87M -24,678 -52%
VOYA Investment Management
144
VOYA Investment Management
Georgia
$1.74M +$358K +4,738 +26%
SO
145
STRS Ohio
Ohio
$1.66M +$249K +3,300 +18%
PA
146
Profund Advisors
Maryland
$1.65M +$1.63M +21,630 New
SAM
147
Sawgrass Asset Management
Florida
$1.64M -$135K -1,780 -8%
CCI
148
Columbus Circle Investors
$1.63M +$1.61M +21,367 New
AIA
149
Avalon Investment & Advisory
Texas
$1.6M -$10.1K -134 -0.6%
Legal & General Group
150
Legal & General Group
United Kingdom
$1.51M +$451K +5,963 +43%

PRAH Hedge Fund Activity: Q3 2017 in Review

261 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in PRA Health Sciences, Inc. (PRAH) for Q3 2017, worth a combined $4.78B — up 2.5% from $4.66B a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new PRAH positions and 15 closed out — a net gain of 30 holders — while 121 added to existing stakes and 70 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $76.1M. The largest seller was Kohlberg Kravis Roberts & Co, cutting an estimated $718M.

  • 261 institutional investors held PRA Health Sciences, Inc. (PRAH) as of Q3 2017, up from 236 in Q2 2017.
  • Funds reported $4.78B of PRA Health Sciences, Inc. stock for Q3 2017, up 2.5% quarter-over-quarter.
  • 45 funds opened new PRA Health Sciences, Inc. positions in Q3 2017 and 15 closed out, a net change of +30 holders.
  • The largest PRA Health Sciences, Inc. buyer in Q3 2017 was Fidelity Investments, an estimated $76.1M added.
  • The largest PRA Health Sciences, Inc. seller in Q3 2017 was Kohlberg Kravis Roberts & Co, an estimated $718M sold.

Based on aggregated 13F filings for Q3 2017.